ES2285910A1 - Preparing method for sodium hyaluronate formulation for treating wounds, involves formulating sodium hyaluronate and polyethylene glycol in sufficient amount, where excipients with two types of polyethylene glycols are prepared - Google Patents
Preparing method for sodium hyaluronate formulation for treating wounds, involves formulating sodium hyaluronate and polyethylene glycol in sufficient amount, where excipients with two types of polyethylene glycols are prepared Download PDFInfo
- Publication number
- ES2285910A1 ES2285910A1 ES200502190A ES200502190A ES2285910A1 ES 2285910 A1 ES2285910 A1 ES 2285910A1 ES 200502190 A ES200502190 A ES 200502190A ES 200502190 A ES200502190 A ES 200502190A ES 2285910 A1 ES2285910 A1 ES 2285910A1
- Authority
- ES
- Spain
- Prior art keywords
- sodium hyaluronate
- polyethylene glycol
- mortar
- formula
- healing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001223 polyethylene glycol Polymers 0.000 title claims abstract description 13
- 229920002385 Sodium hyaluronate Polymers 0.000 title claims abstract description 12
- 229940010747 sodium hyaluronate Drugs 0.000 title claims abstract description 12
- 239000002202 Polyethylene glycol Substances 0.000 title claims abstract description 11
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 title claims abstract description 11
- 238000000034 method Methods 0.000 title claims abstract description 9
- 239000000546 pharmaceutical excipient Substances 0.000 title claims abstract description 9
- 208000027418 Wounds and injury Diseases 0.000 title claims description 7
- 239000000203 mixture Substances 0.000 title claims description 6
- 206010052428 Wound Diseases 0.000 title claims description 5
- 238000009472 formulation Methods 0.000 title 1
- 239000004570 mortar (masonry) Substances 0.000 claims abstract description 8
- 239000011521 glass Substances 0.000 claims abstract description 7
- 239000007788 liquid Substances 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000008187 granular material Substances 0.000 claims abstract description 4
- 239000007787 solid Substances 0.000 claims abstract description 3
- 238000010298 pulverizing process Methods 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 238000002360 preparation method Methods 0.000 claims description 13
- 230000035876 healing Effects 0.000 claims description 10
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 9
- 229920002674 hyaluronan Polymers 0.000 claims description 9
- 229960003160 hyaluronic acid Drugs 0.000 claims description 9
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 5
- 235000009421 Myristica fragrans Nutrition 0.000 claims description 4
- 239000001115 mace Substances 0.000 claims description 4
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims description 4
- 159000000000 sodium salts Chemical class 0.000 claims description 4
- 230000029663 wound healing Effects 0.000 claims description 4
- -1 sodium hyaluronate compound Chemical class 0.000 claims description 3
- 230000004927 fusion Effects 0.000 claims 1
- 238000000265 homogenisation Methods 0.000 claims 1
- 229940100615 topical ointment Drugs 0.000 claims 1
- 239000002674 ointment Substances 0.000 abstract description 3
- 230000000699 topical effect Effects 0.000 abstract description 3
- 239000002253 acid Substances 0.000 abstract description 2
- 238000001556 precipitation Methods 0.000 abstract 1
- 238000005303 weighing Methods 0.000 abstract 1
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 239000000126 substance Substances 0.000 description 6
- 210000002808 connective tissue Anatomy 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Procedimiento para la elaboración de la fórmula de hialuronato sódico para la curación y cicatrización de heridas.Procedure for the preparation of the formula of sodium hyaluronate for the healing and healing of wounds
La presente invención se refiere a un preparado de ácido hialurónico para la obtención de una pomada de uso tópico para la curación de heridas, obtenida por la asociación de productos químicos en la medida adecuada para la obtención del producto adecuado para la pronta curación y cicatrización de cualquier tipo de herida.The present invention relates to a preparation of hyaluronic acid to obtain an ointment for topical use for wound healing, obtained by the association of chemical products to the extent appropriate for obtaining product suitable for prompt healing and healing of Any type of injury.
La sustancia fundamental del tejido conectivo, que se encuentra entre las fibras de colágena, con las que forma complejos funcionalmente muy importantes para el tejido conectivo, se dispone entre los fibroblastos, depositándose en el lecho de la herida y está constituida por las glucoproteinas fibrosas y los glucosaminglicanos que son mucopolisacáridos ácidos.The fundamental substance of connective tissue, which is among the collagen fibers, with which it forms Functionally important complexes for connective tissue, it is arranged between the fibroblasts, depositing in the bed of the wound and consists of fibrous glycoproteins and glucosaminglicans that are acidic mucopolysaccharides.
Desde los trabajos de Berenson, sabemos que los glucosaminglicanos son sintetizados en el aparato de Golpe de los fibroblastos, que han emigrado al foco de lesión. Químicamente son polímeros constituidos por unidades disacarídicas, compuestas en su mayor porcentaje, por una hexosamina básica, la glucosalina o galactosamina y por un ácido úronico, generalmente el ácido glucurónico, poseyendo gran cantidad de bases sulfatadas lo que le confiere una gran importancia funcional.From Berenson's work, we know that glycosaminglicans are synthesized in the Coup apparatus of fibroblasts, which have migrated to the site of injury. Chemically are polymers constituted by disacarid units, composed in their higher percentage, for a basic hexosamine, glucosaline or galactosamine and by a uric acid, usually the acid glucuronic, possessing a large amount of sulfated bases which It confers great functional importance.
Los glucosaminglicanos se encuentran unidos en forma covalente lábil con un proteoglucano o proteína portadora teniendo la constancia de que la síntesis de los glucosaminglicanos se realiza a mayor velocidad que la de la colágena.The glucosaminglicanos are united in labile covalent form with a proteoglycan or carrier protein bearing in mind that the synthesis of glycosaminglicans It is done at a faster rate than that of the collagen.
Respecto a la función de los glucosaminglicanos se piensa que interacciones electrostáticas entre los grupos químicos electronegativos de las cadenas laterales sulfatadas de los glucosaminglicanos y los aminoácidos electropositivos del colágeno son responsables de organizar los componentes macromoleculares de las matrices extracelulares mediante la estabilización del tejido conectivo.Regarding the role of glycosaminglicans it is thought that electrostatic interactions between the groups electronegative chemicals of sulfated side chains of glucosaminglicans and electropositive amino acids of collagen are responsible for organizing the components macromolecular extracellular matrices by means of stabilization of connective tissue.
De igual manera, las cargas negativas de los glucosaminglicanos harán que también interacciones fuertemente con las moléculas de agua, siendo por este motivo, por el que sus elevados momentos bipolares les permiten formar una matriz fuertemente hidratada que cumple la función de resistir las fuerzas de compresión, mientras que al colágeno le corresponde el aporte de la resistencia a la tensión. Las dos funciones de resistir a la compresión y a la tensión, influyen entre sí, ya que la debilidad a la compresión sobrecarga a las fibras colágenas que pueden fragmentarse al faltarles el almohadillado hidráulico de los glucosaminglicanos.Similarly, the negative charges of glycosaminglicans will also make you strongly interact with the water molecules, being for this reason, why their high bipolar moments allow them to form a matrix strongly hydrated that fulfills the function of resisting forces compression, while the contribution of collagen corresponds to Tensile strength The two functions of resisting the compression and tension, influence each other, since the weakness to compression overload to collagen fibers that can fragment by missing the hydraulic padding of the glycosaminglicans
El procedimiento para la elaboración de la fórmula de hialuronato sódico, comprende el preparado de sal sódica de ácido hialurónico al 1,5%, en base de polietilenglicol 4000 y 400, ha demostrado clínicamente una gran eficacia en la síntesis de la sustancia fundamental del tejido conjuntivo de granulación, así como en la estimulación de la aparición del nuevo epitelio; todo ello durante el proceso de cicatrización de las heridas y especialmente en su fase anabólica.The procedure for the elaboration of the Sodium hyaluronate formula, includes the preparation of sodium salt 1.5% hyaluronic acid, based on polyethylene glycol 4000 and 400, clinically demonstrated great efficacy in the synthesis of the fundamental substance of the granulation connective tissue as well as in the stimulation of the appearance of the new epithelium; all this during the wound healing process and especially in its anabolic phase.
La aportación del preparado a lo ya existente se fundamenta especialmente en su concentración de ácido hialurónico del 1,5%. Aunque inicialmente se utilizaron otras concentraciones al 0,5%, 10/0 y 2%, resultando la concentración del 1,5% la que mejores resultados terapéuticos conseguía, a la vez que no aparecían otras reacciones adversas.The contribution of the preparation to the existing is especially based on its concentration of hyaluronic acid 1.5% Although other concentrations were initially used at 0.5%, 10/0 and 2%, resulting in the concentration of 1.5% which better therapeutic results achieved, while not other adverse reactions appeared.
De igual manera, el excipiente seleccionado, el polietilenglicol 4000 y 400, constituye el vehículo hidrosoluble idóneo, para la distribución homogénea, tanto de la sustancia activa el ácido hialurónico, como de la totalidad del compuesto.Similarly, the selected excipient, the polyethylene glycol 4000 and 400, constitutes the water-soluble vehicle suitable for the homogeneous distribution of both the substance activates hyaluronic acid, as of the entire compound.
La concentración de ácido hialurónico al 1,5% ha demostrado su efectividad terapéutica, lo que no ocurre a otras concentraciones más bajas, mientras que concentraciones más altas han presentado problemas de sensibilización cutánea, especialmente del tipo de las dermatitis, que a la concentración referida del 1,5% en ninguno de los casos ha presentado problemas de ninguna etiología.The 1.5% hyaluronic acid concentration has proven therapeutic effectiveness, which does not happen to others lower concentrations, while higher concentrations have had skin sensitization problems, especially of the type of dermatitis, which at the referred concentration of 1.5% in none of the cases has presented problems of any etiology.
A su vez, el preparado de ácido hialurónico, puede asociarse a preparados de colágena, potenciando su eficacia terapéutica, de manera que el ácido hialurónico es el responsable de participar activamente en la síntesis de la sustancia fundamental proporcionándole a la colágena sintetizada un entorno ideal para conseguir un gran resultado cicatricial.In turn, the hyaluronic acid preparation, It can be associated with collagen preparations, enhancing its effectiveness therapeutic, so that hyaluronic acid is responsible to actively participate in the synthesis of the substance fundamental providing the synthesized collagen with an environment Ideal to achieve a great scar result.
La fórmula se compone de hialuronato sódico a 1,5% y polietilenglicol en cantidad suficiente para la obtención de 100 g, utilizando para su obtención vaso de precipitados, mortero y maza de vidrio, probeta, varilla de vidrio y espátula, balanza de precisión y recipiente para baño maría.The formula is composed of sodium hyaluronate a 1.5% and polyethylene glycol in sufficient quantity to obtain 100 g, using a beaker, mortar and glass mace, test tube, glass rod and spatula, balance precision and water bath container.
La preparación galénica comprende un primer paso que consiste en la elaboración del excipiente. Para ello se utilizan dos tipos de polietilenglicol, uno sólido al 15% (polietilenglicol 4000) y otro líquido al 85% (polietilenglicol 400). Se pesan ambas cantidades con ayuda de la balanza y se introducen en un vaso de precipitados. Calentando ambos excipientes en un baño maría se consigue fundir ambas fases para su mezclado.The galenic preparation comprises a first step which consists in the elaboration of the excipient. To do this they use two types of polyethylene glycol, one solid at 15% (polyethylene glycol 4000) and another 85% liquid (polyethylene glycol 400). Both quantities are weighed with the help of the balance and introduced into a beaker. Heating both excipients in a water bath you can melt both phases for your mixed.
En un mortero de vidrio se introducen 1,5 g de sal sódica de ácido hialurónico, previamente pesados. Se trata de un granulado blanco que deberá ser trabajado con la maza del mortero hasta su completa pulverización. Una vez bien molido se adiciona una pequeña cantidad de polietilenglicol 400 líquido y se mezcla bien hasta adquirir una perfecta homogeneidad.In a glass mortar 1.5 g of Sodium salt of hyaluronic acid, previously weighed. Is about a white granulate that must be worked with the mace of the mortar until completely sprayed. Once well ground it add a small amount of liquid polyethylene glycol 400 and it Mix well until you get a perfect homogeneity.
Como fase final para la obtención del acabado de la fórmula prevista para su utilización, a la sal sódica de ácido hialurónico con la mezcla de una pequeña cantidad de polietilenglicol 400, se le adiciona el excipiente previamente preparado, cuando alcanza la temperatura ambiente, consiguiendo una pasta de uso tópico conformando una pomada para la curación y cicatrización de las heridas.As the final phase for obtaining the finish of the formula intended for use, to the acidic sodium salt hyaluronic with mixing a small amount of polyethylene glycol 400, the excipient is added previously prepared, when it reaches room temperature, getting a topical paste forming an ointment for healing and wound healing.
Estimando ampliamente descritas todas y cada una de las partes, composiciones y preparados que constituyen el procedimiento para la elaboración de la fórmula de hialuronato sódico para la curación y cicatrización de heridas objeto del presente registro, solamente nos resta consignar la posibilidad de que en la fórmula obtenida podrán incluirse diversos componentes aromáticos o de otro tipo que permitan mejorar su acabado, siempre que los ingredientes adicionados y sus diversas composiciones incorporadas no sean capaces de alterar los puntos esenciales de que es objeto el presente registro de Patente de Invención.Estimating widely described each and every one of the parts, compositions and preparations that constitute the procedure for the preparation of the hyaluronate formula sodium for the healing and healing of wounds subject to present record, we only have to record the possibility of that in the formula obtained various components may be included aromatic or other that allow to improve its finish, always that the added ingredients and their various compositions incorporated may not alter the essential points that The present invention patent register is the subject.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200502190A ES2285910B1 (en) | 2005-09-08 | 2005-09-08 | PROCEDURE FOR THE ELABORATION OF THE FORMULA OF SODIUM HYALURONATE FOR THE HEALING AND CICATRIZATION OF WOUNDS. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200502190A ES2285910B1 (en) | 2005-09-08 | 2005-09-08 | PROCEDURE FOR THE ELABORATION OF THE FORMULA OF SODIUM HYALURONATE FOR THE HEALING AND CICATRIZATION OF WOUNDS. |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2285910A1 true ES2285910A1 (en) | 2007-11-16 |
ES2285910B1 ES2285910B1 (en) | 2008-12-16 |
Family
ID=38654307
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES200502190A Active ES2285910B1 (en) | 2005-09-08 | 2005-09-08 | PROCEDURE FOR THE ELABORATION OF THE FORMULA OF SODIUM HYALURONATE FOR THE HEALING AND CICATRIZATION OF WOUNDS. |
Country Status (1)
Country | Link |
---|---|
ES (1) | ES2285910B1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05194248A (en) * | 1991-05-24 | 1993-08-03 | Takeda Chem Ind Ltd | External preparation for preventing and treating dermatitis |
JPH08217666A (en) * | 1995-02-10 | 1996-08-27 | Mikimoto Pharmaceut Co Ltd | Oil-in-water type cream base |
US20020127196A1 (en) * | 2000-11-28 | 2002-09-12 | Focal, Inc. | Polyalkylene glycol viscosity-enhancing polymeric formulations |
US20040137079A1 (en) * | 2003-01-08 | 2004-07-15 | Cook James N. | Contact lens and eye drop rewetter compositions and methods |
-
2005
- 2005-09-08 ES ES200502190A patent/ES2285910B1/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05194248A (en) * | 1991-05-24 | 1993-08-03 | Takeda Chem Ind Ltd | External preparation for preventing and treating dermatitis |
JPH08217666A (en) * | 1995-02-10 | 1996-08-27 | Mikimoto Pharmaceut Co Ltd | Oil-in-water type cream base |
US20020127196A1 (en) * | 2000-11-28 | 2002-09-12 | Focal, Inc. | Polyalkylene glycol viscosity-enhancing polymeric formulations |
US20040137079A1 (en) * | 2003-01-08 | 2004-07-15 | Cook James N. | Contact lens and eye drop rewetter compositions and methods |
Non-Patent Citations (1)
Title |
---|
[en línea] [recuperado el 10.10.2007]. Recuperado de: EPO WPI Database; DW 199335; nº acceso 1993-278207 [35]. & JP 05194248 A (TAKEDA CHEM IND LTD) 03.08.1993 (resumen) * |
Also Published As
Publication number | Publication date |
---|---|
ES2285910B1 (en) | 2008-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2427938C (en) | Novel temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution, composition and preparation thereof | |
Kang et al. | Oxygen-generating alginate hydrogels as a bioactive acellular matrix for facilitating wound healing | |
Kisiel et al. | Improving the osteogenic potential of BMP-2 with hyaluronic acid hydrogel modified with integrin-specific fibronectin fragment | |
CA2636050C (en) | Methods for regulating gelation of polysaccharide solutions and uses thereof | |
Lambricht et al. | The type and composition of alginate and hyaluronic-based hydrogels influence the viability of stem cells of the apical papilla | |
RU2508115C2 (en) | Injection composition of polydeoxyribonucleotides for treating osteoarticular diseases | |
KR102056144B1 (en) | Fluid composition containing higher concentrations of fragmented DNA mixtures and a method for manufacturing the same | |
CN107105724A (en) | Protein compositions derived from fibroin | |
ES2815598T3 (en) | Liquid pharmaceutical composition | |
Jiang et al. | Galactosylated chitosan-g-PEI/DNA complexes-loaded poly (organophosphazene) hydrogel as a hepatocyte targeting gene delivery system | |
Li et al. | Physical characterization of a chitosan‐based hydrogel delivery system | |
CN103826608A (en) | Formulations of deoxycholic acid and salts thereof | |
KR20210066860A (en) | Sustained delivery of angiopoietin-like 3 polypeptides | |
CN107735084A (en) | Composition comprising at least one polyalcohol and at least one anesthetic | |
TR201809034T4 (en) | Composition with bio-regenerative, restorative and eutrophic activity. | |
Dang et al. | Rational formulation design of injectable thermosensitive chitosan-based hydrogels for cell encapsulation and delivery | |
CN106265536A (en) | Bortezomib pharmaceutical composition and preparation method thereof | |
Rizwan et al. | Gelatin-based NIR and reduction-responsive injectable hydrogels cross-linked through IEDDA click chemistry for drug delivery application | |
ES2285910B1 (en) | PROCEDURE FOR THE ELABORATION OF THE FORMULA OF SODIUM HYALURONATE FOR THE HEALING AND CICATRIZATION OF WOUNDS. | |
Bae et al. | Development of novel photopolymerizable hyaluronic acid/heparin-based hydrogel scaffolds with a controlled release of growth factors for enhanced bone regeneration | |
Wang et al. | Mito-battery: Micro-nanohydrogel microspheres for targeted regulation of cellular mitochondrial respiratory chain | |
TWI670069B (en) | Composition for maintaining effect of filler | |
Hoque et al. | Microgel-Assisted Delivery of Adenosine to Accelerate Fracture Healing | |
KR101706515B1 (en) | Injectable composition for prevention of depilation or improvement of hair growth | |
JP6134081B1 (en) | Peptide composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EC2A | Search report published |
Date of ref document: 20071116 Kind code of ref document: A1 |
|
FG2A | Definitive protection |
Ref document number: 2285910B1 Country of ref document: ES |
|
PC2A | Transfer of patent |
Owner name: LUCIA TORMO MARTINEZ Effective date: 20190125 |